Search

everythinglearnresearchcommunity

for

Search:↓

Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.

Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.

Oral mTOR inhibitors often cause skin and hair side effects but usually don't require stopping treatment.

The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.

The treatment was ineffective in humans.

CXXC5 can both suppress and promote cancer, making it a complex target for treatment.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

Activated ras can protect kidney cells from a certain substance that causes cell death.

Strontium ranelate is no longer available for treatment.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Tofacitinib may help regrow hair in alopecia areata patients.

Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

More research and guidelines are needed for managing prostate cancer in people with high-risk genetic mutations.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

A rare type of skin cancer with mucosal involvement was partially treated but eventually relapsed.

Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.

Six key genes can predict bladder cancer outcomes and may serve as prognostic biomarkers.

BBR-SA nanomedicine is a safe and effective treatment for breast cancer.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

A new MBTPS2 gene variant disrupts fat metabolism and collagen production, causing Osteogenesis imperfecta.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.

A woman developed severe bladder inflammation after cancer treatment with Cytoxan.